There were 1,744 press releases posted in the last 24 hours and 425,607 in the last 365 days.

ZELTIQ to Present at the Piper Jaffray 27th Annual Healthcare Conference


/EINPresswire.com/ -- PLEASANTON, CA--(Marketwired - November 24, 2015) - ZELTIQ® (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, is scheduled to present at the Piper Jaffray 27th Annual Healthcare Conference in New York City.

Event: Piper Jaffray 27th Annual Healthcare Conference
Date: Tuesday, December 1, 2015
Time: 10:00 am ET / 7:00 am PT

Audio webcast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's web site at www.coolsculpting.com. A replay of the presentation will be available for 90 days.

About ZELTIQ® Aesthetics

ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.


Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.